(MedPage Today) — The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced.
Aficamten is an allosteric and reversible inhibitor of cardiac myosin motor activity…
Source link : https://www.medpagetoday.com/cardiology/chf/119130
Author :
Publish date : 2025-12-22 17:06:00
Copyright for syndicated content belongs to the linked Source.
